Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5705340 | Ophthalmology | 2017 | 8 Pages |
Abstract
Intravitreal injections of anti-VEGF medications increased annually from 2006 to 2015. Bevacizumab was the most common medication used, despite its lacking U.S. Food and Drug Administration approval to treat ophthalmic disease, and AMD was the most common condition treated. Ranibizumab use declined after 2014 while both the absolute and relative use of bevacizumab and aflibercept increased.
Keywords
DRCR.netDMEAMDRVOPDRFDADiabetic macular edemaRetinal vein occlusionICDdiabetic retinopathyProliferative diabetic retinopathyFood and Drug Administrationage-related macular degenerationDiabetic Retinopathy Clinical Research NetworkInternational Classification of DiseasesVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ravi MD, MPH, Joseph S. MD, MHS, Lindsey R. MPH, Ron A. MD, MPH, Nilay D. PhD, Andrew J. MD,